Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

INTRODUCTION: Dupilumab is approved as first-line systemic treatment for adults/adolescents with moderate-to-severe atopic dermatitis (AD) in Europe and elsewhere owing to its favourable benefit–risk profile. However, systemic non-steroidal immunosuppressants (NSISS) are often used as first-line the...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, Christopher, de Bruin-Weller, Marjolein, Deleuran, Mette, Fargnoli, Maria Concetta, Staumont-Sallé, Delphine, Hong, Chih-ho, Sánchez-Carazo, Jose, Foley, Peter, Seo, Seong Jun, Msihid, Jérôme, Chen, Zhen, Cyr, Sonya L., Rossi, Ana B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322347/
https://www.ncbi.nlm.nih.gov/pubmed/34142350
http://dx.doi.org/10.1007/s13555-021-00558-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322347/
https://www.ncbi.nlm.nih.gov/pubmed/34142350
http://dx.doi.org/10.1007/s13555-021-00558-0

Ejemplares similares